PROVINCIAL STANDARDS & GUIDELINES

PROVINCIAL STANDARDS & GUIDELINES

NxStage Nursing Manual Created: August 2015 Revised: December 2016 Approved by the Home Hemodialysis Committee PROVINCIAL STANDARDS & GUIDELINES

  Guidelines, Standards, Provincial, Provincial standards amp guidelines

Warming Peritoneal Dialysis Solutions - BC Renal …

in peritoneal dialysis solution degrades to compounds known as glucose degradation products (GDP’s). Extensive glucose degradation

  Solutions, Dialysis, Peritoneal, Peritoneal dialysis, Peritoneal dialysis solution

Major drug interactions with cyclosporine and …

Major drug interactions with cyclosporine and tacrolimus Major drug interactions with cyclosporine (CsA) and tacrolimus (TAC):1,2 éé ncreased I immunosuppressant concentration êê Decreased immunosuppressant concentration

  With, Drug, Major, Interactions, Tacrolimus, Lycopersicon, Major drug interactions with cyclosporine and, Major drug interactions with cyclosporine and tacrolimus major drug interactions with cyclosporine

VASCULAR ACCESS GUIDELINE Rope Ladder Cannulation of …

2 Rope Ladder Cannulation of AV Fistulas and Grafts • Approved May 2013 BC Provincial Renal Agency • Suite 700-1380 Burrard St. • Vancouver, BC • V6Z 2H3 • 604.875.7340 • BCRenalAgency.ca

  Graft

Management of PRURITUS in Patients with Chronic …

Management of PRURITUS in Patients with Chronic Kidney Disease 1 of 10 BC Renal Agency • Suite 700-1380 Burrard St. • Vancouver, BC • V6Z 2H3 • 604.875.7340 • BCRenalAgency.ca Aug 2017

  Patients, With, Management, Disease, Kidney, Chronic, Management of pruritus in patients with chronic, Pruritus, Management of pruritus in patients with chronic kidney disease

ACLS Drug Overview - CME Associates

(VASOPRESSOR) Indicated in cardiac arrest. Increases heart rate, increase contractility and peripheral vascular resistance. Standard Arrest Dose: 1 mg IV q3-5 min (1:10,000).

  Drug, Overview, Acls, Acls drug overview

ANTICOAGULANT, THROMBOLYTIC, and ANTI …

Med 6541 Hematopoiesis and Host Defences Spring 2006 Dr. Janet Fitzakerley 307 Med jfitzake@d.umn.edu Anticoagulants www.d.umn.edu/~jfitzake Page 1 of 21

  Anticoagulant, Thrombolytic

DOCTOR’S ORDERS INTRAPLEURAL t-PA and D …

HR-01-178 11/03/14 rev. 03/06/15 Page 1 of 2 PATIENT LABEL DOCTOR’S ORDERS INTRAPLEURAL t-PA and D-Nase ADMINISTRATION ORDERS Adult Critical Care and Telemetry Units ONLY

  Order, Doctors, Doctor s orders intrapleural t pa and, Intrapleural

Infusion Therapy - Central Line Occlusion and TPA

HHVNA Infusion Therapy – CENTRAL LINE: OCCLUSION AND TPA 10 mL saline flush Heparin flush per agency policy PROCEDURE: 1. …

  Line, Central, Therapy, Infusion, Occlusion, Infusion therapy central line occlusion and, Infusion therapy central line, Occlusion and

LABETALOL Class: Beta-Blocker with Alpha …

LABETALOL Class: Beta-Blocker with Alpha-Blocking Activity Indications Treatment of mild-to-severe hypertension; I.V. for severe hypertension , Pediatric

  With, Activity, Class, Alpha, Bates, Blockers, Blocking, Labetalol class, Labetalol, Beta blocker with alpha, Beta blocker with alpha blocking activity

Intravenous Medication Safety and Smart Infusion …

Abstract •••• Carol A. Keohaneis Project Director for the Center of Excellence for Patient Safety Research and Practice at Brigham and Women’s Hospital, Boston, Mass. The Center’s efforts are aimed at improving medication safety across clinical settings.

let’s talk about Stroke, TIA and Warning Signs

Prevention This must be done within six hours to 24 hours of the first symptoms of stroke and only after the patient has received IV Alteplase.

  Alteplase

Intraluminal Volume Dose Alteplase for the …

Hospital Pharmacy 203 Intraluminal Alteplase for Occluded PICC Lines Alteplase, also known as tissue plasminogen activator (tPA), is a fibrinolytic agent indicated for

  Volume, Dose, Intraluminal volume dose alteplase for, Intraluminal, Alteplase